Shares of Merck & Co., Inc. (NYSE:MRK) jumped 0.39% to reach at $58.66 during the course of session. The company has experienced volume of 8.49M shares while on average the company has a capacity of trading 9.66M shares.
Merck & Co., Inc. (NYSE:MRK) has just announced that its Ebola vaccine candidate, VSV-ZEBOV has been granted FDA's BreakthroughTherapy Designation alongside European Medicine Agency (EMA) Priority Medicines (PRIME) status.
A study of analyst recommendations at the major brokerages shows that Merck & Co., Inc. is the #15 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel.
The affected fluoroquinolones brands include Avelox (moxifloxacin) from Merck & Co., Inc. (NYSE:MRK), Cipro (ciprofloxacin) from Bayer AG (ADR) (OTCMKTS:BAYRY), Factive (gemifloxacin) from Oscient Pharmaceuticals Corp.
Feinstein Doyle Payne & Kravec LLC and Sanford Heisler, LLP have revealed that more than 400 women had already reached out with discrimination claims relating to the $250 million women discrimination class action lawsuit against Merck & Co., Inc.